Vyne Therapeutics Inc expected to post a loss of 30 cents a share - Earnings Preview
24/02/2025 14:19
* Vyne Therapeutics Inc VYNE.OQ VYNE.O is expected
to show a
rise in quarterly revenue when it reports results on February
26 (estimated) for the period ending December 31 2024
* The Bridgewater New Jersey-based company is expected to
report
a 84.2% increase in revenue to $140 thousand from $76 thousand a
year ago, according to the mean estimate from 2 analysts, based
on LSEG data.
* LSEG's mean analyst estimate for Vyne Therapeutics Inc is
for a
loss of 30 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Vyne
Therapeutics
Inc is $5.88, above its last closing price of $2.74.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Sep. 30 2024 -0.23 -0.23 -0.29 Missed -23.4
Jun. 30 2024 -0.19 -0.19 -0.22 Missed -15.8
Mar. 31 2024 -0.24 -0.24 -0.15 Beat 37.5
Dec. 31 2023 -0.50 -0.50 -0.20 Beat 60
Sep. -0.76 -0.76 -2.01 Missed -164.5
30 2023
Jun. 30 2023 -1.99 -1.99 -3.09 Missed -55.3
Mar. 31 2023 -2.59 -2.61 -1.74 Beat 33.3
Dec. 31 2022 -3.24 -3.24 -3.33 Missed -2.8
This summary was machine generated February 24 at 14:19 GMT.
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)